PANDHA-25-P-0000_003354 DNA Aptamer-based Therapeutic Development
Closed Special Notice Posted
- Solicitation number
- PANDHA-25-P-0000_003354_
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- 8(a) Sole Source
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Krung Thep Maha Nakhon Thailand
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency has issued a Special Notice for a sole source contract opportunity related to DNA aptamer-based therapeutic development. The Notice of Intent was published on April 3, 2025, and is being managed by the United States Army Medical Research Acquisition Activity (USAMRAA). The contract specifically targets scientific research focused on developing antimicrobial agents to combat bacterial wound infections. Nanohmics Inc. has been identified as the intended contractor for this two-year scientific study targeting the bacterial pathogen Pseudomonas aeruginosa. The opportunity is classified under the 8(a) Sole Source acquisition method and falls within the Research and Development in Biotechnology NAICS category.
The primary objective of this contract is to develop DNA aptamers by producing and conjugating them with C1q and Fc domain proteins, with research to be conducted at Walter Reed Army Institute of Research (WRAIR) and Armed Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok, Thailand. Interested contractors may submit capability information in writing by 2:00 p.m. Eastern Time on April 17, 2025, to Ms. Linda Hinson via email at linda.t.hinson.civ@health.mil. While responses will be evaluated, the government retains sole discretion to determine whether to compete the procurement. If no responses are received, USAMRAA will proceed with the direct sole source contract with Nanohmics Inc. under Federal Acquisition Regulation (FAR) 13.501. The research aims to validate the binding capabilities of the developed aptamers and ultimately create a biologic therapeutic solution for bacterial wound infections.
Notice text
See attached Notice of Intent.
Files
| File | Type | Posted |
|---|---|---|
| A02-Notice of Intent to Sole Source PANDHA-25-P-0000 003354.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Special Notice | |
| PANDHA-25-P-0000_003354 DNA Aptamer-based Therapeutic Development | Pre-Solicitation |
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity